Adil Daud
Overview
Explore the profile of Adil Daud including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
15464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haugh A, Osorio R, Francois R, Tawil M, Tsai K, Tetzlaff M, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38611025
Background: Cutaneous melanoma (CM) can be molecularly classified into four groups: mutant, mutant, mutant and triple wild-type (TWT) tumors lacking any of these three alterations. In the era of immune...
2.
Feichtenschlager V, Chen L, Zheng Y, Ho W, Sanlorenzo M, Vujic I, et al.
Mol Cancer
. 2024 Feb;
23(1):40.
PMID: 38383439
Finding effective therapeutic targets to treat NRAS-mutated melanoma remains a challenge. Long non-coding RNAs (lncRNAs) recently emerged as essential regulators of tumorigenesis. Using a discovery approach combining experimental models and...
3.
Feichtenschlager V, Chen L, Zheng Y, Ho W, Sanlorenzo M, Vujic I, et al.
Res Sq
. 2023 Dec;
PMID: 38077055
Finding effective therapeutic targets to treat NRAS-mutated melanoma remains a challenge. Long non-coding RNAs (lncRNAs) recently emerged as essential regulators of tumorigenesis. Using a discovery approach combining experimental models and...
4.
Campana L, Daud A, Lancellotti F, Arroyo J, Davalos R, Di Prata C, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444450
The 4th World Congress of Electroporation (Copenhagen, 9-13 October 2022) provided a unique opportunity to convene leading experts in pulsed electric fields (PEF). PEF-based therapies harness electric fields to produce...
5.
Haugh A, Daud A
Cancer Immunol Res
. 2023 Jun;
11(7):864.
PMID: 37262325
Resistance to immune checkpoint blockade (ICB), a subject of increasing interest and relevance in the current cancer treatment landscape, is likely induced by several different and incompletely understood mechanisms, including...
6.
De Braud F, Dooms C, Heist R, Lebbe C, Wermke M, Gazzah A, et al.
J Clin Oncol
. 2023 Mar;
41(14):2651-2660.
PMID: 36947734
Purpose: No approved targeted therapy for the treatment of patients with neuroblastoma RAS viral (v-ras) oncogene homolog ()-mutant melanoma is currently available. Patients And Methods: In this phase Ib escalation/expansion...
7.
Zheng Y, Ho W, Sanlorenzo M, Vujic I, Daud A, Algazi A, et al.
Melanoma Res
. 2022 Aug;
32(6):411-418.
PMID: 35993892
Immunosuppressive therapy is standard for the treatment of inflammatory diseases and for minimizing rejection in transplant patients. However, immunosuppressant drugs are associated with an increased risk of certain cancers. In...
8.
Lee J, Nguyen B, Mukhopadhyay A, Han M, Zhang J, Gujar R, et al.
Mol Ther Oncolytics
. 2022 May;
25:174-188.
PMID: 35592387
Clinical studies have demonstrated that local expression of the cytokine IL-12 drives interferon-gamma expression and recruits T cells to the tumor microenvironment, ultimately yielding durable systemic T cell responses. Interrogation...
9.
Wu C, Chow M, Temby M, McCalmont T, Daud A
JCO Precis Oncol
. 2022 Jan;
5:340-343.
PMID: 34994598
No abstract available.
10.
Hamid O, Robert C, Daud A, Carlino M, Mitchell T, Hersey P, et al.
Eur J Cancer
. 2021 Sep;
157:391-402.
PMID: 34571336
Objective: Patients with melanoma and early stable disease (SD) with pembrolizumab have unclear prognosis. We present post hoc analyses of long-term outcomes for patients with early SD, partial response (PR) ...